deletions | additions       diff --git a/section_Drug_resistance_Global_and__.tex b/section_Drug_resistance_Global_and__.tex  index 60bc7d9..4687a38 100644  --- a/section_Drug_resistance_Global_and__.tex  +++ b/section_Drug_resistance_Global_and__.tex 
...
\section{Drug resistance}  Global and regional estimates of the proportion of new and retreatment cases of TB that had MDR-TB in 2014 were calculated using country-level information. If countries had reported data on the proportion of new and retreatment cases of TB that have MDR-TB from routine surveillance or a survey of drug resistance the latest available information was used. For data from routine surveillance to be considered representative, at least 60\% of notified new pulmonary TB cases must have a documented DST result for at least rifampicin. For countries that have not reported such data, estimates of the proportion of new and retreatment cases of TB that have MDR-TB were produced using modelling (including multiple imputation) that was based on data from countries for which data do exist. Estimates for countries without data were based on countries that were considered to be similar in terms of TB epidemiology (for country groups see Appendix 1). Figure \ref{fig:epiregions}).  The observed and imputed estimates of the proportion of new and retreatment cases of TB that have MDR-TB were then pooled to give a global estimate, with countries weighted according to their share of global notifications of new and retreatment cases. \subsection{MDR-TB mortality}